Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) affects different people in different ways. Most infected people develop mild to moderate illness and recover without hospitalization. This case report presents a patient who had difficulty eradicating the corona virus due to being treated with rituximab, which depletes B lymphocytes and therefore disables the production of neutralizing antibodies. The regen-COV-2 antibody cocktail consists of two monoclonal antibodies, casirivimab and imdevimab. This cocktail successfully helped the patient's immune system eradicate the virus without auto specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production. In vitro studies confirm that eradication of the intact the virus. This case report emphases the importance of providing external antiviral antibodies regularly, like the regen-COV-2 antibody cocktail, as post- and even pre- SARS-CoV-2 infection prophylaxis in patients treated with rituximab.
| Original language | English |
|---|---|
| Pages (from-to) | 695-696 |
| Number of pages | 2 |
| Journal | Israel Medical Association Journal |
| Volume | 24 |
| Issue number | 11 |
| State | Published - Nov 2022 |
Bibliographical note
Funding Information:The authors thank the directors and medical teams of the department of Internal Medicine at the Galilee Medical Center, Nahariya, Israel, for their help and support.
Funding
The authors thank the directors and medical teams of the department of Internal Medicine at the Galilee Medical Center, Nahariya, Israel, for their help and support.
| Funders | Funder number |
|---|---|
| Galilee Medical Center |
Keywords
- Regen-COV-2 antibody cocktail
- coronavirus disease 2019 (COVID-19)
- neutralizing antibodies
- rituximab
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)